KR970042550A - Cdch의 신규 결정성 변형체, 그의 제조 방법 및 이 변형체를 함유하는 제약 제제 - Google Patents

Cdch의 신규 결정성 변형체, 그의 제조 방법 및 이 변형체를 함유하는 제약 제제 Download PDF

Info

Publication number
KR970042550A
KR970042550A KR1019960064345A KR19960064345A KR970042550A KR 970042550 A KR970042550 A KR 970042550A KR 1019960064345 A KR1019960064345 A KR 1019960064345A KR 19960064345 A KR19960064345 A KR 19960064345A KR 970042550 A KR970042550 A KR 970042550A
Authority
KR
South Korea
Prior art keywords
cdch
monohydrate
variants
compound according
anhydrous
Prior art date
Application number
KR1019960064345A
Other languages
English (en)
Other versions
KR100525146B1 (ko
Inventor
알폰스 그루넨베르크
패트릭 보쉐
Original Assignee
컨터 슈마허, 클라우스 로이터
바이엘 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7779831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR970042550(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 컨터 슈마허, 클라우스 로이터, 바이엘 악티엔게젤샤프트 filed Critical 컨터 슈마허, 클라우스 로이터
Publication of KR970042550A publication Critical patent/KR970042550A/ko
Application granted granted Critical
Publication of KR100525146B1 publication Critical patent/KR100525146B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 1-시클로프로필-7-([S,S]-2,8-디아자비시클로-[4,3,0]논-8-일)-6-플루오로-1,4-디히드로-8-메톡시-4-옥소-3-퀴놀린카르복실산 히드로클로라이드 (CDCH)의 신규 일수화물, 그의 제조 방법 및 활성 화합물로서 일수화물을 함유하는 제약 제제에 관한 것이다.

Description

CDCH의 신규 결정성 변형체, 그의 제조 및 이 변형체를 함유하는 제약 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
내용없음

Claims (10)

13C-NMR 스펙트럼에서는 168.1 ppm에서 특성 피크를 가지고 X선 회절도 에서는 2Θ=26.7에서 띠를 가진 하기 화학식 1의 CDCH 일수화물
제1항에 있어서, 사방결정형인 화합물.
무수 CDCH를 화학양론적 양의 결정화수가 흡수되고 결정의 변환이 종결될 때까지 완전히 혼합 및 수화하기에 충분한 양 이상의 물로 처리한 후에, 이와 같이 하여 얻어진 일수화물의 결정을 분리하고, 남아있는 흡수된 물을 제거하는 것이 특징인 제1항에 따른 CDCH 일수화물의 제조방법.
제3항에 있어서, 수성 매질 중의 무수 CDCH의 현탁액을 수화 및 결정 변환이 종결될 때까지 교반하는 것이 특징인 방법.
제3항에 있어서, 사방결정형 일수화물을 제조하기 위해서는, 화학양론적으로 충분하되 10% 이하의 물 함량을 가진 매질 중에 침상 무수 CDCH 또는 CDCH 일수화물을 용해시킨 다음, 용매를 제거하는 것이 특징인 방법.
제3항에 있어서, 무수 CDCH가 결정이 정량적으로 변환될 때까지 습기에 노출시키는 것이 특징인 방법.
제1항 또는 제2항에 따른 화합물을 함유하는 약제.
제1항 또는 제2항에 따른 화합물을 함유하는 항균 제제.
제1항 또는 제2항에 따른 화합물의 용도.
제1항 또는 제2항에 따른 화합물의 약제 제조 용도.
KR1019960064345A 1995-12-12 1996-12-11 Cdch의신규결정성변형체,그의제조방법및이변형체를함유하는 항균 조성물 KR100525146B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19546249A DE19546249A1 (de) 1995-12-12 1995-12-12 Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE19546249.1 1995-12-12

Publications (2)

Publication Number Publication Date
KR970042550A true KR970042550A (ko) 1997-07-24
KR100525146B1 KR100525146B1 (ko) 2006-01-27

Family

ID=7779831

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960064345A KR100525146B1 (ko) 1995-12-12 1996-12-11 Cdch의신규결정성변형체,그의제조방법및이변형체를함유하는 항균 조성물

Country Status (42)

Country Link
US (1) US5849752A (ko)
EP (1) EP0780390B1 (ko)
JP (1) JP4104687B2 (ko)
KR (1) KR100525146B1 (ko)
CN (1) CN1061348C (ko)
AR (1) AR005009A1 (ko)
AT (1) ATE221531T1 (ko)
AU (1) AU708006B2 (ko)
BG (1) BG62258B1 (ko)
BR (1) BR9605968A (ko)
CA (1) CA2192418C (ko)
CO (1) CO4480105A1 (ko)
CU (1) CU22774A3 (ko)
CZ (1) CZ288657B6 (ko)
DE (2) DE19546249A1 (ko)
DK (1) DK0780390T3 (ko)
EE (1) EE03474B1 (ko)
ES (1) ES2179910T3 (ko)
HR (1) HRP960558B1 (ko)
HU (1) HU226521B1 (ko)
ID (1) ID22625A (ko)
IL (1) IL119795A (ko)
IN (1) IN185805B (ko)
MA (1) MA24342A1 (ko)
MY (1) MY117492A (ko)
NL (1) NL300109I1 (ko)
NO (1) NO306725B1 (ko)
NZ (1) NZ299905A (ko)
PL (1) PL184885B1 (ko)
PT (1) PT780390E (ko)
RO (1) RO119782B1 (ko)
RU (1) RU2162468C2 (ko)
SA (1) SA96170492B1 (ko)
SG (1) SG47201A1 (ko)
SI (1) SI0780390T1 (ko)
SK (1) SK282805B6 (ko)
SV (1) SV1996000109A (ko)
TR (1) TR199600970A2 (ko)
TW (1) TW411340B (ko)
UA (1) UA35638C2 (ko)
YU (1) YU49485B (ko)
ZA (1) ZA9610405B (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL192273B1 (pl) * 1997-09-25 2006-09-29 Bayer Ag Preparat środka leczniczego w postaci pastylki o kontrolowanej dyfuzji lub w postaci układu matrycowego, o kontrolowanym uwalnianiu substancji czynnej
DE19751948A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
HU229065B1 (en) 1998-11-10 2013-07-29 Bayer Ip Gmbh Pharmaceutical moxifloxacin compositions
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) * 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
EP1562942A1 (en) * 2002-10-31 2005-08-17 Ranbaxy Laboratories, Ltd. Amorphous moxifloxacin hydrochloride
US7230006B2 (en) * 2003-04-09 2007-06-12 Reddy's Laboratories Limited Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof
US20060264635A1 (en) * 2003-08-05 2006-11-23 Chava Satyanarayana Process for the preparation of moxifloxacin hydrochloride
ITMI20032259A1 (it) 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
ES2319125T3 (es) * 2003-11-20 2009-05-04 Chemi S.P.A. Polimorfos del clorhidrato del acido 1-ciclopropil-7-((s,s)-2,8-diazadiciclo(4.3.0)-non-8-il)-6-fluoro-1,4-dihidro-8-metoxi-4-oxo-3-quinolina carboxilico y metodos para la preparacion de los mismos.
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
EP2032521B1 (en) 2006-06-27 2009-10-28 Sandoz AG New method for salt preparation
ES2303768B1 (es) * 2006-09-08 2009-06-05 Quimica Sintetica, S.A. Nueva forma cristalina de moxifloxacino clorhidrato.
AU2007320997B2 (en) 2006-11-13 2012-11-08 Cipla Limited Process for the synthesis of moxifloxacin hydrochloride
EP1992626A1 (en) * 2007-05-10 2008-11-19 Sandoz AG Process for the preparation of moxifloxacin hydrochloride
EP2083010A1 (en) * 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
CN102176902B (zh) * 2008-10-09 2012-10-31 阿卜迪易卜拉欣贸易公司 有机溶剂在莫西沙星湿法造粒中的应用
EP2342204A1 (en) * 2008-11-06 2011-07-13 Hetero Research Foundation Novel polymorph of moxifloxacin hydrochloride
WO2010066385A1 (de) 2008-12-08 2010-06-17 Ratiopharm Gmbh Kompaktiertes moxifloxacin
EP2429991B1 (en) 2009-05-15 2014-09-10 Redx Pharma Limited Redox drug derivatives
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN102924449B (zh) * 2012-10-30 2015-08-12 重庆福安药业集团庆余堂制药有限公司 盐酸莫西沙星h晶型及其制备方法和药物组合物
US9388178B2 (en) 2012-12-04 2016-07-12 Mankind Research Centre Process for the preparation of moxifloxacin hydrochloride
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
EP2969004A4 (en) 2013-03-15 2016-09-21 Melinta Therapeutics Inc METHOD FOR THE TREATMENT OF INFECTIONS IN OVERWEIGHT AND ADIPOSIVE PATIENTS USING ANTIBIOTICS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601567A1 (de) * 1986-01-21 1987-07-23 Bayer Ag 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate
CN1019114B (zh) * 1986-03-31 1992-11-18 三共株式会社 喹啉-3-羟酸衍生物的制备方法
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
TW209865B (ko) 1992-01-10 1993-07-21 Bayer Ag
DE69331003T2 (de) * 1992-01-31 2002-06-20 Chugai Seiyaku K.K., Tokio/Tokyo Kristalle von derivaten von chinozon carbonsäure-hydraten
DE4234078A1 (de) 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
NO301165B1 (no) * 1992-12-25 1997-09-22 Daiichi Seiyaku Co Bicykliske aminderivater og antibakterielle midler inneholdende disse
ZA946853B (en) * 1993-09-10 1995-04-24 Daiichi Seiyaku Co Crystals of antimicrobial compound.
DE69504392T2 (de) * 1994-04-07 1999-02-11 Pfizer Inc., New York, N.Y. Verwendung von Trovafloxacin oder dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung von H.Pylori Infektionen

Also Published As

Publication number Publication date
EP0780390A1 (de) 1997-06-25
CA2192418C (en) 2001-06-12
ATE221531T1 (de) 2002-08-15
SK159196A3 (en) 1997-10-08
PT780390E (pt) 2002-11-29
DE19546249A1 (de) 1997-06-19
NZ299905A (en) 1998-09-24
NL300109I1 (nl) 2003-02-03
TW411340B (en) 2000-11-11
HU226521B1 (en) 2009-03-30
SI0780390T1 (en) 2002-10-31
ID22625A (id) 1999-12-02
IL119795A (en) 1998-12-27
CO4480105A1 (es) 1997-07-09
HRP960558A2 (en) 1998-02-28
CZ288657B6 (cs) 2001-08-15
NO306725B1 (no) 1999-12-13
UA35638C2 (uk) 2001-04-16
ES2179910T3 (es) 2003-02-01
JP4104687B2 (ja) 2008-06-18
IN185805B (ko) 2001-05-05
SV1996000109A (es) 1997-10-23
MA24342A1 (fr) 1998-07-01
AU708006B2 (en) 1999-07-29
MY117492A (en) 2004-07-31
BG101043A (en) 1998-04-30
EE9600201A (et) 1997-06-16
NO965298D0 (no) 1996-12-11
ZA9610405B (en) 1997-06-23
RO119782B1 (ro) 2005-03-30
SG47201A1 (en) 1998-03-20
TR199600970A2 (tr) 1997-06-21
JPH09169757A (ja) 1997-06-30
AU7421696A (en) 1997-06-19
AR005009A1 (es) 1999-04-07
DE59609501D1 (de) 2002-09-05
SA96170492B1 (ar) 2006-05-23
CN1160052A (zh) 1997-09-24
US5849752A (en) 1998-12-15
YU49485B (sh) 2006-08-17
EE03474B1 (et) 2001-08-15
SK282805B6 (sk) 2002-12-03
CN1061348C (zh) 2001-01-31
HUP9603428A3 (en) 1997-10-28
HUP9603428A2 (en) 1997-08-28
MX9606325A (es) 1997-10-31
RU2162468C2 (ru) 2001-01-27
HRP960558B1 (en) 2002-04-30
DK0780390T3 (da) 2002-11-11
YU65096A (sh) 1998-12-23
CZ364696A3 (en) 1997-07-16
NO965298L (no) 1997-06-13
CA2192418A1 (en) 1997-06-13
KR100525146B1 (ko) 2006-01-27
PL184885B1 (pl) 2003-01-31
BG62258B1 (bg) 1999-06-30
CU22774A3 (es) 2002-07-24
HU9603428D0 (en) 1997-01-28
PL317415A1 (en) 1997-06-23
IL119795A0 (en) 1997-03-18
BR9605968A (pt) 1998-08-18
EP0780390B1 (de) 2002-07-31

Similar Documents

Publication Publication Date Title
KR970042550A (ko) Cdch의 신규 결정성 변형체, 그의 제조 방법 및 이 변형체를 함유하는 제약 제제
RU2000102914A (ru) Кристаллическая модифицированная форма n-фенил-2-пиримидинаминового производного, способы ее получения и ее применение
US3707534A (en) Method for production of lactulose concentrate
FI75571C (fi) Framstaellningsfoerfarande foer synnerligen kristalliniskt natriumcefoperazon.
JPH0585933A (ja) 白内障治療用薬剤
PT84597A (en) Process for the preparation of compositions for increasing crop yield containing malonic acid derivatives as well as of novel malonic acid derivatives
US4054738A (en) Sodium cefamandole crystalline forms
US20210323959A1 (en) Methods for purifying isavuconazonium sulfate
PT78942B (fr) Procede de preparation de nouveaux derives de l'acide 4-phenyl 4-oxo buten-2-oique
DE60003679T2 (de) Polymorphe eines kristallinen azabicyclo(2,2,2) octan-3-amin citrat und diesen enthaltenden arzneimitteln
DD261163A5 (de) Verfahren zur reinigung von cephalosporin-antibiotika
US3013007A (en) Neomycin salt of higher fatty acids
FI62311C (fi) Foerfarande foer framstaellning av kristallint natrium- och kaiumcefalexinmonohydrat
RU2126402C1 (ru) Способ селективного получения 3/2 гидрата 7-[(7-(s)-амино-5-азаспиро [2,4] гептан- 5-ил]-8-хлор-6-фтор-1- [(1r, 2s)-2-фторциклопропил]-4-оксо-1,4-дегидрохинолин-3- карбоновой кислоты, безводная 7-[(7-(s)-амино-5-азаспиро [2,4] гептан-5-ил]-8-хлор-6- фтор-1- (1r, 2s)-2-фторциклопропил-4-оксо-1,4-дигидрохинолин-3-карбоновая кислота и фармацевтическая композиция, обладающая антибактериальной активностью
US4849417A (en) Acetylsalicylic acid derivative and pharmaceutical composition thereof
US4168376A (en) Process for crystalline sodium cefamandole
EP0261823B1 (en) Stable hydrate of penicillin derivative and process for preparing same
KR860001495B1 (ko) 결정성 나트륨 세포페라존의 제조방법
RU2074858C1 (ru) Кристаллический дигидрат (5r, 6s)-2-карбамоилоксиметил-6-[(1r)-гидроксиэтил]-2-пенем-3-карбоновой кислоты, способ его получения, фармацевтическая композиция
DE3378980D1 (en) Benzazepine derivatives, process for their preparation and their use as pharmaceutical compounds
EP0039967A1 (en) Solvate of amoxicillin, process for the preparation thereof and process for the preparation of injectable preparations from this solvate
CA1089447A (en) Sodium cefamandole crystalline forms
GB2118933A (en) Saccharin derivative
EP0225796A2 (en) Novel crystals of N alpha-[[(S)-4-oxo-2-azetidinyl]-carbonyl]-L-histidyl-L-prolinamide and process for producing the crystals
CA1089446A (en) Sodium cefamandole crystalline forms

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
N231 Notification of change of applicant
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20131001

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20140930

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20151002

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20160929

Year of fee payment: 12

EXPY Expiration of term